2026-10-07 Company
Tempus Expands Collaboration with Moderna and Merck to Support INT Commercialization Tempus to handle sequencing and sample logistics for mRNA-4157 with Keytruda potential commercialization
D1 +4.8% · since +0.3%
2026-10-02 Capital Bull
Moderna to Join Nasdaq-100 Index on October 9 Inclusion in Nasdaq-100 triggers passive buying from index funds, boosting liquidity and institutional attention
D1 +0.6% · since +3.7%
22 earlier events › 2026-09-14 → 10-02 Product Bear
Moderna Up 37% in Sept; Citi Warns of 60% Plunge Citi downgrades to Sell citing overextended rally, yet buyers step in, widening bull-bear divide
D1 +1.9% · +5d +17.9%
› 10 waves of this story2026-09-14 AI-driven personalized cancer vaccine met Phase 3 endpoint in adjuvant melanoma with Merck; company cites broader multi-tumor push2026-09-16 Zacks reports positive Phase III results showing significant improvements in recurrence-free and distant metastasis-free survival2026-09-22 First mRNA cancer vaccine to pass Phase 3; data to be presented Oct 24; stock hits 52-week high2026-09-22 Multiple sources confirm ESMO late-breaking abstract, market eyes October data release2026-09-23 CEO and management at Bernstein forum highlight mRNA platform and personalized cancer vaccine intismeran, setting up October Phase 3 data.2026-09-25 Shares near $198; Bernstein reiterates Market Perform with $45 PT2026-09-26 Multiple independent sources confirm new 52-week high and strong performance, extending prior uptrend2026-09-28 NewEdge lifts stake 208%; stock nears top YTD performer, traders keep discussing2026-09-29 Stock continues to climb with high market attention, but no new facts, just repetition.2026-10-02 Citi downgrades to Sell citing overextended rally, yet buyers step in, widening bull-bear divide2026-09-30 8-K filing
8-K: Item 5.02, Item 7.01, Item 9.01 D1 -5.4% · +5d +2.0%
2026-09-30 Analyst
Citigroup downgrades to Sell D1 -5.4% · +5d +2.0%
2026-09-12 → 09-24 Capital
Moderna Sees Institutional Position Changes and Bullish Options Flow Institutional selling and new buying coexist, with bullish options activity indicating heightened interest and divergent views
D1 +1.9% · +5d +17.9%
› 2 waves of this story2026-09-12 Amundi trimmed 1.8% while X posts highlight short squeeze and money flow, showing mixed sentiment2026-09-24 Institutional selling and new buying coexist, with bullish options activity indicating heightened interest and divergent views2026-09-06 → 09-17 Product Bull
Moderna Cancer Vaccine Momentum Extends, Stock Up 137% in Month Multiple sources confirm stock extends monthly rally, no fresh disclosure, continuation of prior event
D1 -3.6% · +5d +2.5%
› 5 waves of this story2026-09-06 Multiple reports highlight breakthrough mRNA cancer vaccine results, boosting oncology pipeline expectations2026-09-07 Moderna bets mRNA's second act on cancer; +394% YTD, 2nd best in S&P 5002026-09-08 Multiple sources highlight progress on melanoma vaccine, drawing high market attention2026-09-15 Price holds high while selling volume dries up; traders see it ready to move again, extending prior rally2026-09-17 Multiple sources confirm stock extends monthly rally, no fresh disclosure, continuation of prior event2026-09-11 Other
Lawmaker Trades MRNA on Day of Vaccine News Two sources flag same-day trades, raising insider trading concerns
D1 +5.4% · +5d +7.0%
2026-09-02 → 09-04 Product Bear
GSK Advances mRNA Flu Vaccine Phase III, Intensifying Competition with Moderna GSK's mRNA flu vaccine advancement directly challenges Moderna's FDA-approved mFlusiva
D1 -2.2% · +5d -9.4%
› 2 waves of this story2026-09-02 GSK to start Phase III mRNA flu vaccine in Sept, signaling heightened competition in mRNA space2026-09-04 GSK's mRNA flu vaccine advancement directly challenges Moderna's FDA-approved mFlusiva2026-09-03 Analyst
Rothschild & Co downgrades to Sell D1 -1.3% · +5d -3.3%
2026-09-03 Analyst Bear
Moderna Downgraded to Sell, PT Raised to $81 Rothschild Redburn sees strong melanoma data but valuation prices in broad use
D1 -1.3% · +5d -3.3%
2026-09-02 8-K filing
8-K: Item 1.01, Item 2.03, Item 3.02, Item 8.01 D1 -2.2% · +5d -9.4%
2026-08-28 Regulation
FDA clears updated COVID shots incl. Moderna's 2026-27 season approvals for Moderna, Pfizer, Novavax-Sanofi
D1 -3.3% · +5d +5.5%
2026-08-28 Analyst
Argus Research upgrades to Buy D1 -3.3% · +5d +5.5%
2026-08-25 Analyst
Wolfe Research upgrades to Peer Perform D1 +14.4% · +5d -2.9%
2026-08-19 Analyst
William Blair upgrades to Outperform D1 +177.0% · +5d -14.2%
2026-08-06 → 08-07 Regulation Bull
FDA Approves Moderna's First mRNA Flu Vaccine mFLUSIVA FDA approves Moderna's first mRNA flu vaccine for adults 50+, with supply expected in select retailers in coming weeks.
D1 -4.3% · +5d +18.2%
› 2 waves of this story2026-08-06 Multi-source confirmed; new option for seniors; fifth approved product globally2026-08-07 FDA approves Moderna's first mRNA flu vaccine for adults 50+, with supply expected in select retailers in coming weeks.2026-08-05 Insider selling Bear
Insider selling $28.7M (1) D1 -1.3% · +5d +13.2%
2026-07-31 Earnings
Earnings report 2026年全年营收增长指引维持在最高10%，预计全年美国与国际市场收入占比约50/50，第三季度营收约占下半年营收的55%。
D1 -5.4% · +5d +7.9%
2026-07-25 → 07-31 Earnings
Moderna to Report Earnings Next Week, Market Awaits Results Q2 revenue $145M misses, GAAP EPS -$1.97, norovirus vaccine disappoints
D1 +2.9% · +5d -0.9%
› 2 waves of this story2026-07-25 Multiple sources confirm Moderna's earnings next week; Zacks analyzes potential miss2026-07-31 Q2 revenue $145M misses, GAAP EPS -$1.97, norovirus vaccine disappoints2026-07-31 8-K filing
8-K: Item 2.02, Item 9.01 D1 -5.4% · +5d +7.9%
2026-07-31 Product Bear
Moderna Norovirus Vaccine Misses Phase 3 Expectations mRNA-1403 missed early success bar, impacting pipeline prospects
D1 -5.4% · +5d +7.9%
2026-07-31 Earnings
Moderna Q2 Revenue Beats but Loss Widens Q2 revenue of $145M beat estimates, EPS loss of $1.97, but COVID vaccine sales weak
D1 -5.4% · +5d +7.9%
2026-07-08 8-K filing
8-K: Item 5.02, Item 7.01, Item 9.01 D1 -7.5% · +5d -7.5%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
